New Aspects of Cancer Stem Cell Biology : Implications for Innovative Therapies

The cancer stem cell (CSC) paradigm represents one of the most prominent breakthroughs of the last decades in tumor biology. CSCs are that subpopulation within a tumor that can survive conventional therapies and as a consequence are able to fuel tumor recurrence. Nevertheless, the biological charact...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2020
Language:English
Physical Description:1 electronic resource (208 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993546313204498
ctrlnum (CKB)5400000000040926
(oapen)https://directory.doabooks.org/handle/20.500.12854/69328
(EXLCZ)995400000000040926
collection bib_alma
record_format marc
spelling Cavallaro, Ugo edt
New Aspects of Cancer Stem Cell Biology Implications for Innovative Therapies
New Aspects of Cancer Stem Cell Biology
Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
1 electronic resource (208 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
The cancer stem cell (CSC) paradigm represents one of the most prominent breakthroughs of the last decades in tumor biology. CSCs are that subpopulation within a tumor that can survive conventional therapies and as a consequence are able to fuel tumor recurrence. Nevertheless, the biological characteristics of CSCs and even their existence, remain the main topic among tumor biologists debates. The difficulty in achieving a better definition of CSC biology may actually be explained by the plasticity of such a cell subpopulation. Indeed, the emerging view is that CSCs represent a dynamic “state” of tumor cells that can acquire stemness-related properties under specific circumstances, rather than referring to a well-defined group of cells. Regardless of their origin, it is clear that designing novel antitumor treatments based on the eradication of CSCs will only be possible upon unraveling the biological mechanisms that underlie their pathogenic role in tumor progression and therapy resistance. The Special Issue on “New aspects of cancer stem cell biology: implications for innovative therapies” aims at highlighting recent insights into CSC features that can make them an attractive target for novel therapeutic strategies.
English
Research & information: general bicssc
Biology, life sciences bicssc
Cadherin 11
WNT signaling
β-catenin
cancer stem cells
TNBC
early breast cancer
bevacizumab
neoadjuvant chemotherapy
ALDH1
solid cancer
chemo-resistance
HDAC inhibitors
head and neck squamous cell carcinoma
SRC
dasatinib
saracatinib
EC-8042
Ovarian cancer
Wnt signaling
tumor progression
therapy resistance
exosomes
oral cancer risk
oral epithelial dysplasia
SOX2
immunohistochemistry
oral squamous cell carcinoma
genome-wide
transcriptome
lung cancer
ATAC-seq
RNA-seq
CSCs
NSCLC
B4GALT1
LUAD
breast cancer
lipid
metabolism
therapeutic resistance
bowel cancer
organoid
tumoroid
colorectal
colon
stem cell
chemotherapy resistance
ovarian cancer
cancer stem cell
genetic heterogeneity
SNP array
L1CAM
chemoresistance
epithelial-mesenchymal transition
cancer therapy
cell adhesion molecule
3-03943-406-3
3-03943-407-1
Giordano, Marco edt
Cavallaro, Ugo oth
Giordano, Marco oth
language English
format eBook
author2 Giordano, Marco
Cavallaro, Ugo
Giordano, Marco
author_facet Giordano, Marco
Cavallaro, Ugo
Giordano, Marco
author2_variant u c uc
m g mg
author2_role HerausgeberIn
Sonstige
Sonstige
title New Aspects of Cancer Stem Cell Biology Implications for Innovative Therapies
spellingShingle New Aspects of Cancer Stem Cell Biology Implications for Innovative Therapies
title_sub Implications for Innovative Therapies
title_full New Aspects of Cancer Stem Cell Biology Implications for Innovative Therapies
title_fullStr New Aspects of Cancer Stem Cell Biology Implications for Innovative Therapies
title_full_unstemmed New Aspects of Cancer Stem Cell Biology Implications for Innovative Therapies
title_auth New Aspects of Cancer Stem Cell Biology Implications for Innovative Therapies
title_alt New Aspects of Cancer Stem Cell Biology
title_new New Aspects of Cancer Stem Cell Biology
title_sort new aspects of cancer stem cell biology implications for innovative therapies
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2020
physical 1 electronic resource (208 p.)
isbn 3-03943-406-3
3-03943-407-1
illustrated Not Illustrated
work_keys_str_mv AT cavallarougo newaspectsofcancerstemcellbiologyimplicationsforinnovativetherapies
AT giordanomarco newaspectsofcancerstemcellbiologyimplicationsforinnovativetherapies
AT cavallarougo newaspectsofcancerstemcellbiology
AT giordanomarco newaspectsofcancerstemcellbiology
status_str n
ids_txt_mv (CKB)5400000000040926
(oapen)https://directory.doabooks.org/handle/20.500.12854/69328
(EXLCZ)995400000000040926
carrierType_str_mv cr
is_hierarchy_title New Aspects of Cancer Stem Cell Biology Implications for Innovative Therapies
author2_original_writing_str_mv noLinkedField
noLinkedField
noLinkedField
_version_ 1787548866839576576
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04079nam-a2201009z--4500</leader><controlfield tag="001">993546313204498</controlfield><controlfield tag="005">20231214132827.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000040926</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/69328</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000040926</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Cavallaro, Ugo</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New Aspects of Cancer Stem Cell Biology</subfield><subfield code="b">Implications for Innovative Therapies</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">New Aspects of Cancer Stem Cell Biology </subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (208 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The cancer stem cell (CSC) paradigm represents one of the most prominent breakthroughs of the last decades in tumor biology. CSCs are that subpopulation within a tumor that can survive conventional therapies and as a consequence are able to fuel tumor recurrence. Nevertheless, the biological characteristics of CSCs and even their existence, remain the main topic among tumor biologists debates. The difficulty in achieving a better definition of CSC biology may actually be explained by the plasticity of such a cell subpopulation. Indeed, the emerging view is that CSCs represent a dynamic “state” of tumor cells that can acquire stemness-related properties under specific circumstances, rather than referring to a well-defined group of cells. Regardless of their origin, it is clear that designing novel antitumor treatments based on the eradication of CSCs will only be possible upon unraveling the biological mechanisms that underlie their pathogenic role in tumor progression and therapy resistance. The Special Issue on “New aspects of cancer stem cell biology: implications for innovative therapies” aims at highlighting recent insights into CSC features that can make them an attractive target for novel therapeutic strategies.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Research &amp; information: general</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biology, life sciences</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cadherin 11</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">WNT signaling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">β-catenin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer stem cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TNBC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">early breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bevacizumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neoadjuvant chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ALDH1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">solid cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemo-resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HDAC inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">head and neck squamous cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SRC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dasatinib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">saracatinib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EC-8042</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Ovarian cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Wnt signaling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor progression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">exosomes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oral cancer risk</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oral epithelial dysplasia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SOX2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunohistochemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oral squamous cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genome-wide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transcriptome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lung cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ATAC-seq</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RNA-seq</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CSCs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NSCLC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">B4GALT1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">LUAD</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lipid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bowel cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">organoid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumoroid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">colorectal</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">colon</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stem cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemotherapy resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ovarian cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer stem cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genetic heterogeneity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SNP array</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">L1CAM</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemoresistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epithelial-mesenchymal transition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell adhesion molecule</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-406-3</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-407-1</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giordano, Marco</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cavallaro, Ugo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giordano, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:32:28 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338166580004498&amp;Force_direct=true</subfield><subfield code="Z">5338166580004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338166580004498</subfield></datafield></record></collection>